Brodalumab, A new molecule, the anti-IL-17 receptor A monoclonal antibody can block IL-17A and IL-25 signaling, effective only in asthmatic patients with high IL-17, consistent with late-onset obesity-related asthma. Here, IL17A is linked to obesity due to melanocortin 4 receptor deficiency.